Maluping R P, Paul N C, Moodley A
Br J Biomed Sci. 2014;71(2):55-7. doi: 10.1080/09674845.2014.11669965.
Staphylococcus pseudintermedius is a leading aetiologic agent of pyoderma and other body tissue infections in dogs and cats. In recent years, an increased prevalence of methicillin-resistant S. pseudintermedius (MRSP) has been reported. Isolation of MRSP in serious infections poses a major therapeutic challenge as strains are often resistant to all forms of systemic antibiotic used to treat S. pseudintermedius -related infections. This study investigates the occurrence of MRSP from a total of 7183 clinical samples submitted to the authors' laboratories over a 15-month period. Identification was based on standard microbiological identification methods, and by S. pseudintermedius-specific nuc polymerase chain reaction (PCR). Methicillin resistance was confirmed by PBP2a latex agglutination and mecA PCR. Susceptibility against non-beta-lactam antibiotics was carried out using a disc-diffusion method according to Clinical and Laboratory Standards Institute (CLSI) guidelines. In addition, susceptibility to pradofloxacin--a new veterinary fluoroquinolone--was also investigated. SCCmec types were determined by multiplex PCR. Staphylococcus pseudintermedius was isolated from 391 (5%) samples and 20 were confirmed as MRSP from cases of pyoderma, otitis, wound infections, urinary tract infection and mastitis in dogs only. All 20 isolates were resistant to clindamycin and sulphamethoxazole/trimethoprim. Nineteen were resistant to chloramphenicol, enrofloxacin, gentamicin, marbofloxacin and pradofloxacin; additionally, seven isolates were resistant to tetracycline. Fifteen isolates carried SCCmec type II-III, four isolates had type V and one harboured type IV. To date, only a few scientific papers on clinical MRSP strains isolated from the UK have been published, thus the results from this study would provide additional baseline data for further investigations.
中间型葡萄球菌是犬猫脓皮病及其他身体组织感染的主要病原体。近年来，耐甲氧西林中间型葡萄球菌（MRSP）的患病率有所上升。在严重感染中分离出MRSP带来了重大治疗挑战，因为这些菌株通常对用于治疗与中间型葡萄球菌相关感染的所有形式的全身抗生素均耐药。本研究调查了在15个月期间提交至作者实验室的总共7183份临床样本中MRSP的发生情况。鉴定基于标准微生物鉴定方法以及中间型葡萄球菌特异性核酸酶聚合酶链反应（PCR）。通过PBP2a乳胶凝集试验和mecA PCR确认甲氧西林耐药性。根据临床和实验室标准协会（CLSI）指南，采用纸片扩散法检测对非β-内酰胺类抗生素的敏感性。此外，还研究了对新型兽用氟喹诺酮类药物普拉德氟沙星的敏感性。通过多重PCR确定SCCmec类型。仅从犬的脓皮病、中耳炎、伤口感染、尿路感染和乳腺炎病例中，从391份（5%）样本中分离出中间型葡萄球菌，其中20份被确认为MRSP。所有20株分离株均对克林霉素和磺胺甲恶唑/甲氧苄啶耐药。19株对氯霉素、恩诺沙星、庆大霉素、马波沙星和普拉德氟沙星耐药；此外，7株对四环素耐药。15株携带SCCmec II-III型，4株为V型，1株为IV型。迄今为止，仅发表了几篇关于从英国分离出的临床MRSP菌株的科学论文，因此本研究结果将为进一步研究提供额外的基线数据。
